A phase II study of modified degramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer

Cancer Investigation

Volumn 21, Issue 4, 2003, Pages 505-511

  Ryan, David P ^a,c   Clark, Jeffrey W ^a   Kulke, Matthew H ^a   Fuchs, Charles S ^a   Earle, Craig C ^a   Enzinger, Peter C ^a   Stuart, Keith ^b   Catarius, Keith J ^a   Winkelmann, Jennifer ^a   Mayer, Robert J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141565275     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120022359     Document Type: Article

References (19)

1. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; et al. Cancer statistics, 2001. Ca: Cancer J. Clin. 2001, 51, 15-36.
2. Nordic Gastrointestinal Tumor Adjuvant Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 1992, 10, 904-911.
3. Allen-Mersh, T.G.; Earlam, S.; Fordy, C.; et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344, 1255-1260.
4. Rougier, P.; Van Cutsem, E.; Bajetta, E.; et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352, 1407-1412.
5. Cunningham, D.; Pyrhonen, S.; James, R.D.; et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352, 1413-1418.
6. Douillard, J.Y.; Cunningham, D.; Roth, A.D.; et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355, 1041-1047.
7. Saltz, L.B.; Cox, J.V.; Blanke, C.; et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group. N. Engl. J. Med. 2000, 343, 905-914.
8. Machover, D.; Diaz-Rubio, E.; de Gramont, A.; et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 1996, 7, 95-98.
9. Becouarn, Y.; Ychou, M.; Ducreux, M.; et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 1998, 16, 2739-2744.
10. Bertheault-Cvitkovic, F.; Jami, A.; Ithzaki, M.; et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 1996, 14, 2950-2958.
11. Giacchetti, S.; Perpoint, B.; Zidani, R.; et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000, 18, 136-147.
12. Zori Comba, A.; Blajman, C.; Richardet, E.; et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur. J. Cancer 2001, 37, 1006-1013.
13. Andre, T.; Bensmaine, M.A.; Louvet, C.; et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999, 17, 3560-3568.
14. Martoni, A.; Mini, E.; Pinto, C.; et al. Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann. Oncol. 2001, 12, 519-524.
15. de Gramont, A.; Figer, A.; Seymour, M.; et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938-2947.
16. de Gramont, A.; Vignoud, J.; Tournigand, C.; et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997, 33, 214-219.
17. Van Cutsem, E.; Szanto, J.; Roth, A.; et al. Evaluation of the addition of oxaliplatin to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer. Proc. ASCO 1999, 18, A900.
18. Streit, M.; Jaehde, U.; Stremetzne, S.; et al. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann. Oncol. 1997, 8, 163-165.
19. Tralongo, P.; Di Mari, A.; Scibilia, G.; et al. Prolonged 5-fluorouracil infusion in patients with metastatic colon cancer pretreated with bolus schedule of the same agent. Anticancer Res. 1995, 15, 635-638.